The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in patients with von Willebrand disease.
Age >= 18 years and <= 65 years at the time of signing informed consent, regardless of sex;
At screening, patients with a confirmed diagnosis of von Willebrand disease (VWD) with documented evidence and a defined VWD subtype;
At least 4 new bleeding episodes within 6 months prior to screening;
No active bleeding symptoms prior to the first dose;
Known history of hypersensitivity to the investigational drug formulation or any of its components;
Intolerance to subcutaneous injection or presence of other local skin abnormalities or dermatological conditions that may affect drug administration and safety assessment;
Hemoglobin < 60 g/L;
Platelet count < 80 x 10^9/L;